Kei Sonehara

15PUBLICATIONS
11CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCondensed matter characterisation technique developmentInnate immunityNutrigenomics and personalised nutrition
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|May 22, 2026
Real-World Data of Second-Line Amrubicin Monotherapy in Patients With Extensive-Stage Small Cell Lung Cancer Who Received First-Line Chemoimmunotherapy or Chemotherapy: A Multicenter Retrospective Study.

|Dec 07, 2024
Real-World Study of EGFR-TKI Rechallenge With Another TKI After First-Line Osimertinib Discontinuation in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study.

Kei Sonehara, Kazunari Tateishi, Kiyotaka Yoh

|Aug 03, 2024
Evaluation of the association between predictive factors and the development of immune-related adverse events and prognostic factors for chemoimmunotherapy in patients with non-small cell lung cancer: A multicenter retrospective study.

Ryota Ozawa, Kei Sonehara, Tsutomu Hachiya

|Jan 13, 2023
C-PLAN index as a prognostic factor for patients with previously untreated advanced non-small cell lung cancer who received combination immunotherapy: A multicenter retrospective study.

Kei Sonehara, Ryota Ozawa, Mineyuki Hama

|Oct 04, 2022
Is using a consolidation tumor ratio 0.5 as criterion feasible in daily practice? Evaluation of interobserver measurement variability of consolidation tumor ratio of lung cancer less than 3 cm in size.

Sachie Koike, Kimihiro Shimizu, Shogo Ide

|May 26, 2022
Predictive value of post-treatment C-reactive protein-to-albumin ratio in locally advanced non-small cell lung cancer patients receiving durvalumab after chemoradiotherapy.

Taisuke Araki, Kazunari Tateishi, Masamichi Komatsu

Pageof 3

Frequent Collaborators

9 joint publications

Kazunari Tateishi

5 joint publications

Taisuke Araki

4 joint publications

Tomonobu Koizumi

2 joint publications

Shintaro Kanda